EBV VLP Vaccine
Prevention of Epstein-Barr Virus infection and associated Infectious Mononucleosis (IM)
Pre-clinicalActive
Key Facts
Indication
Prevention of Epstein-Barr Virus infection and associated Infectious Mononucleosis (IM)
Phase
Pre-clinical
Status
Active
Company
About EBViously
EBViously is a private, pre-clinical stage biotech developing a novel VLP vaccine for Epstein-Barr virus. The company is tackling a significant unmet medical need, as EBV is a widespread pathogen with no approved vaccine, linked to acute infectious mononucleosis and serious long-term health risks. Operating from Munich, Germany, the firm is in the early stages of advancing its vaccine candidate, positioning itself in a competitive and high-potential segment of infectious disease prevention. Its success hinges on demonstrating clinical efficacy and navigating the complex development pathway for a first-in-class EBV vaccine.
View full company profile